The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...
BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback